CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7108 result(s)

Consultation for Patients on the Deliberative Appraisal Process at CADTH

Event Date: February 11, 2021
Result type: Events

The top three principles for the deliberative process identified by the Health Technology Assessment International 2020 Global Policy Forum were transparency, inclusivity, and impartiality. CADTH has worked with a few patient groups to create a two-part consultation to support wide participation: first, an education session — How CADTH Expert C...

How CADTH Expert Committees Deliberate

Event Date: February 4, 2021
Result type: Events

CADTH has three expert committees that provide recommendations to publicly funded drug programs, health ministries, and health authorities on the appropriate use of drugs, medical devices, and clinical interventions: CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC): cancer drugs CADTH Canadian Drug Expert Committee (CDE...

There’s Always Evidence…

Event Date: January 19, 2021 - February 9, 2021
Result type: Events

There’s solid agreement that decisions in health care that are informed by hard facts are likely to be better than decisions made based on gut instinct or something your brother’s best friend’s second cousin says his grandmother’s neighbour told him. Systematic reviews and meta-analyses are regarded as the gold standard for evidence, but they ar...

onasemnogene abeparvovec (Zolgensma)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: onasemnogene abeparvovec
Indications: ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: Initial

Unresectable Hepatocellular Carcinoma

Last Updated: January 18, 2021
Result type: Reports

Provisional Funding Algorithm Stakeholder Input Deadline Feb 1, 2021 Draft Report Posted (Target) Mar 24, 2021 Stakeholder Feedback Deadline Mar 31, 2021 Final Report Posted (Target) Apr 23, 2021

  • Project Number: PH0003-000

infliximab (TBC)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: infliximab
Indications: Use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis. Reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to a corticosteroid and/or aminosalicylate. Subcutaneous infliximab can be used alone or in combination with conventional therapy. Treatment of fistulising Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment. Reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing, and reduction or elimination of corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy (i.e., aminosalicylate and/or corticosteroid and/or an immunosuppressant).

  • Brand Name: TBC
  • Manufacturer: Celltrion Healthcare Co., Ltd
  • Project Number: SR0659-000
  • Project Status: Active
  • Submission Type: Initial

COVID-19 Update

Last Updated: January 18, 2021
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related t...

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: January 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: Initial

luspatercept (Reblozyl)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: luspatercept
Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

  • Brand Name: Reblozyl
  • Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.
  • Project Number: SR0669-000
  • Project Status: Active
  • Submission Type: Initial

liraglutide (Saxenda)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Active
  • Submission Type: Initial